non-hodgkin's%20lymphoma
NON-HODGKIN'S LYMPHOMA

Non-Hodgkin's lymphoma is a heterogeneous group of lymphoproliferative malignancies.
It is the most common hematologic cancer.
The most common subtypes are the diffuse large B-cell and follicular lymphoma. The subtypes are based on the malignant cell's morphology, genetic features, immunohistological characteristics, and stage of maturation.

Radiotherapy

Indolent Stage I/Contiguous Stage II NHL
  • Studies suggest doses of 25-40 Gy
  • May be given as local or extended-field RT
Aggressive Stage I/Contiguous Stage II NHL
  • Involved site radiation therapy (ISRT) may be given with or without chemotherapy (usually R-CHOP)
    • Studies have shown an increase in the overall survival & event-free survival rates of patients given CHOP with involved-site radiation therapy (ISRT)
Indolent Noncontiguous Stage II/III/IV NHL
  • Studies suggest doses of 25-40 Gy
  • Total body irradiation (TBI), EF-XRT, & TBI followed by high-dose radioimmunotherapy are still under clinical evaluation & needs further studies to prove efficacy in patients with indolent noncontiguous stage II/III/IV NHL
Aggressive Noncontiguous Stage II/III/IV NHL
  • Local-field XRT is recommended with combination chemotherapy
Recurrent NHL
  • Low dose involved site radiation therapy (ISRT) is recommended to indolent/aggressive relapsed NHL patients for palliative purposes
Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Oncology - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
Jackey Suen, 08 Oct 2018

Adding pertuzumab to trastuzumab plus an aromatase inhibitor (AI) improves progression-free survival (PFS) in patients with HER2-positive metastatic or locally advanced breast cancer, the phase II PERTAIN study has shown.

Jackey Suen, 09 Oct 2018

LCL161, an experimental inhibitor of apoptosis (IAP) protein antagonist, is shown to improve pathologic complete response (pCR) when added to paclitaxel in selected patients with localized triple-negative breast cancer (TNBC) in neoadjuvant settings.

01 Dec 2015
Colchine use in male Taiwanese patients with gout is associated with substantially reduced risk for cancer, as shown in a 12-year cohort study.